Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117

Sekeres Mikkael A.; Othus Megan; List Alan F.; Odenike Olatoyosi; Stone Richard M.; Gore Steven D.; Litzow Mark R.; Buckstein Rena; Fang Min; Roulston Diane; Bloomfield Clara D.; Moseley Anna; Nazha Aziz; Zhang Yanming; Velasco Mario R.; Gaur Rakesh; Atallah Ehab; Attar Eyal C.; Cook Elina K.; Cull Alyssa H.; Rauh Michael J.; Appelbaum Frederick R.; Erba Harry P.

首页> 外文期刊>Journal of Clinical Oncology >Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117

【24h】

Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117

机译：单独或与Lenalidomide或与vorinostat的随机氨基氨基或与vorinostat在更高风险的骨髓增生综合征和慢性骨髓细胞白血病中的随机期II研究：北美互动学习扫帚S1117

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Purpose

机译：目的

著录项

来源
《Journal of Clinical Oncology》 |2017年第24期|共16页
作者
Sekeres Mikkael A.; Othus Megan; List Alan F.; Odenike Olatoyosi; Stone Richard M.; Gore Steven D.; Litzow Mark R.; Buckstein Rena; Fang Min; Roulston Diane; Bloomfield Clara D.; Moseley Anna; Nazha Aziz; Zhang Yanming; Velasco Mario R.; Gaur Rakesh; Atallah Ehab; Attar Eyal C.; Cook Elina K.; Cull Alyssa H.; Rauh Michael J.; Appelbaum Frederick R.; Erba Harry P.;
展开▼
作者单位

Cleveland Clin Cleveland OH 44106 USA;

SWOG Stat Ctr Seattle WA USA;

H Lee Moffitt Canc Ctr &

Res Inst Tampa FL USA;

Univ Chicago Chicago IL 60637 USA;

Dana Farber Canc Inst Boston MA 02115 USA;

Yale Univ New Haven CT USA;

Mayo Clin Rochester MN USA;

Sunnybrook Hlth Sci Ctr Toronto ON Canada;

Fred Hutchinson Canc Res Ctr 1124 Columbia St Seattle WA 98104 USA;

Univ Michigan Ann Arbor MI 48109 USA;

Ohio State Univ Ctr Comprehens Canc Columbus OH 43210 USA;

SWOG Stat Ctr Seattle WA USA;

Cleveland Clin Cleveland OH 44106 USA;

Mem Sloan Kettering Canc Ctr 1275 York Ave New York NY 10021 USA;

Heartland NCORP Canc Care Specialists Cent Illinois Decatur IL USA;

Kansas City Natl Canc Inst Community Oncol Res Program Prairie Village KS USA;

Med Coll Wisconsin Milwaukee WI 53226 USA;

Massachusetts Gen Hosp Boston MA 02114 USA;

Queens Univ Kingston ON Canada;

Queens Univ Kingston ON Canada;

Queens Univ Kingston ON Canada;

Fred Hutchinson Canc Res Ctr 1124 Columbia St Seattle WA 98104 USA;

Univ Alabama Birmingham Birmingham AL USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
专利

1. Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117 [J] . Sekeres Mikkael A., Othus Megan, List Alan F., Journal of Clinical Oncology . 2017,第24期

机译：单独或与Lenalidomide或与vorinostat的随机氨基氨基或与vorinostat在更高风险的骨髓增生综合征和慢性骨髓细胞白血病中的随机期II研究：北美互动学习扫帚S1117
2. Comparison of Two Different Therapeutic Regimens with Azacitidine and Lenalidomide (Combined versus Sequential) in Higher-Risk Myelodysplastic Syndromes. Update of Long-Term Results of a Randomized Phase II Multicenter Study [J] . Finelli Carlo, Clissa Cristina, Follo Matilde Y., Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：氮酰硝乙酮和萘丙胺（组合术术肾上腺胺综合征的两种不同治疗方案的比较。更新随机阶段II多中心研究的长期结果
3. A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents [J] . Short Nicholas J., Jabbour Elias, Naqvi Kiran, American Journal of Hematology . 2019,第1期

机译：在低甲基化试剂失效后，少于风险髓细胞增生综合征和慢性骨髓细胞白血病患者的Omacetaxine Mepescate的II期研究
4. Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117 [O] . Mikkael A. Sekeres, Megan Othus, Alan F. List, -1

机译：阿扎胞苷单独或与来那度胺或伏立诺他汀联合治疗高危骨髓增生异常综合征和慢性粒细胞性白血病的随机II期研究：北美小组研究SWOG S1117
5. Azacitidine-eligibility in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukaemia:A registry-based study [O] . Durairaj, Senthilkumar, Keenan, Norene, Hyslop, Ann, 2013

机译：阿扎胞苷在高危骨髓增生异常综合症和慢性粒细胞单核细胞白血病中的资格：基于登记的研究

Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅